Kenneth Rosenfield

Kenneth Rosenfield

MGH

USA USA

Dr. Rosenfield is an international leader, innovator, educator, and master clinician in vascular medicine and interventional cardiology. He served as National PI or Co-PI of numerous landmark clinical trials, including the NIH BEST-CLI trial, as well as HI-PEITHO, ACT 1, Superb, Surveil, Aspire, Artisan, and others. The Aspire 2 and Levant 2 trials that he spearheaded led to the first USFDA approval for renal stents and drug-coated balloons, respectively. As Co-PI of the Flare trial, he ushered in the use of large bore thrombectomy for acute pulmonary embolism. Dr. Rosenfield is past-president of SCAI, served as ACC Governor for Massachusetts, and has both chaired and served on numerous committees for SCAI, ACC, AHA. He founded the NCDR CARE (carotid) Registry and the CREST 2 Registry, wrote the initial standards for carotid stent operators and facilities, and has contributed to many PAD and CVD guidelines documents. He is a founder and long-term board member of VIVA, and he is the inaugural recipient of the LIVE award (Leaders in Vascular Education). Over the course of his storied career, he has trained and mentored countless interventional cardiology and vascular physicians. His leadership and clinical excellence have been widely recognized by the cardiovascular community as the recipient of multiple awards of distinction: the AHA Laennec Master Clinician Award, the TCT Geoffrey Hartzler Master Operator Award, and the SCAI Helping Hearts Lifetime Achievement Award. He is a Master of SCAI. A passionate advocate for multispecialty team-based care, he founded and served as inaugural president of the PERT Consortium, creating a movement that has changed the paradigm for management of pulmonary embolism.

SPEAKER